Report of Objective Clinical Responses in Patients with Brain Cancer to Pharmaceutical-Grade Synthetic Cannabidiol

Abstract

Background/Aim: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of Pharmaceutical-Grade Synthetic Cannabidiol on a range of Brain Tumours Patients and Methods: We analysed the data routinely collected as part of our treatment program in 11 Brain Cancer patients over a fouryear period. Results: Clinical responses were seen in all of these 11 patients, including a reduction in tumour size, as shown by repeat scans. There were no side effects of any kind observed when using Pharmaceutical-Grade Synthetic Cannabidiol. Pharmaceutical-Grade Synthetic Cannabidiol was supplied by STI Pharmaceuticals. Conclusion: Pharmaceutical-Grade Synthetic Cannabidiol is a candidate for treating glioma patients.